Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
31/03/2025 14:32
Brainstorm Cell Therapeutics Inc BCLI.OQ reported a quarterly adjusted loss of 51 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -60 cents. The mean expectation of two analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -49 cents to -27 cents per share. Reported revenue was zero; analysts expected zero. Brainstorm Cell Therapeutics Inc's reported EPS for the quarter was a loss of 51 cents. The company reported a quarterly loss of $2.97 million. Brainstorm Cell Therapeutics Inc shares had fallen by 47.6% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 40.7% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Brainstorm Cell Therapeutics Inc is $10.00 This summary was machine generated from LSEG data March 31 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.38 | -0.51 | Missed |
| Sep. 30 2024 | -0.57 | -0.51 | Beat |
| Jun. 30 2024 | -0.52 | -0.60 | Missed |
| Mar. 31 2024 | -1.05 | -0.75 | Beat |
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview